消息面上，和誉近期发布公告称，于8月27日回购20万股；于8月28日又回购10万股。截至2025年6月30 日，已累计回购954.5万股，合计7530万港元。此外，根据香港联交所披露的文件，AllianzSE于8月15日 增持和誉，增持后，AllianzSE持股比例由4.81%升至5.10%。 中泰证券（600918）指出，公司上半年营收6.57亿元，同比增长20%；净利润3.28亿元，同比增长 59%；账上的现金储备高达23亿元人民币，这为未来的研发和运营提供了坚实的保障。这些增长主要得 益于其核心产品匹米替尼(ABSK021)与默克的合作，2025年上半年默克行使了匹米替尼的全球商业化选 择权，并支付了8500万美元的行权费。展望未来，公司有望伴随匹米替尼全球获批上市、销售持续获得 里程碑付款及销售分成，考虑到公司稳步推进匹米替尼注册上市，公司健康的财务表现具备中期内的可 持续性。 和誉-B(02256)涨超6%，高见18港元再创新高，截至发稿，涨5.56%，报17.84港元，成交额3437.75万港 元。 ...

消息面上，和誉近期发布公告称，于8月27日回购20万股；于8月28日又回购10万股。截至2025年6月30 日，已累计回购954.5万股，合计7530万港元。此外，根据香港联交所披露的文件，AllianzSE于8月15日 增持和誉，增持后，AllianzSE持股比例由4.81%升至5.10%。 中泰证券指出，公司上半年营收6.57亿元，同比增长20%；净利润3.28亿元，同比增长59%；账上的现 金储备高达23亿元人民币，这为未来的研发和运营提供了坚实的保障。这些增长主要得益于其核心产品 匹米替尼（ABSK021）与默克的合作，2025年上半年默克行使了匹米替尼的全球商业化选择权，并支 付了8500万美元的行权费。展望未来，公司有望伴随匹米替尼全球获批上市、销售持续获得里程碑付款 及销售分成，考虑到公司稳步推进匹米替尼注册上市，公司健康的财务表现具备中期内的可持续性。 智通财经APP获悉，和誉-B(02256)涨超6%，高见18港元再创新高，截至发稿，涨5.56%，报17.84港 元，成交额3437.75万港元。 ...

Investment Rating - The report maintains a "Buy" rating for the company, expecting a relative performance increase of over 15% against the benchmark index in the next 6 to 12 months [2][11]. Core Insights - The company has shown strong financial performance with a revenue of 657 million RMB in the first half of 2025, representing a year-on-year growth of 20%, and a net profit of 328 million RMB, up 59% year-on-year [4]. - The company has a robust cash reserve of 2.3 billion RMB, providing solid support for future R&D and operations [4]. - The core product, Pimiatinib (ABSK021), has successfully entered the global commercialization phase with Merck exercising its option and paying a fee of 85 million USD [4]. - The company is expected to achieve significant sales milestones with Pimiatinib's global approval and ongoing sales revenue sharing [4]. - The company is actively repurchasing shares, indicating a focus on shareholder returns, with a total of 9.545 million shares repurchased by June 30, 2025 [7]. Financial Performance and Projections - Revenue projections for 2025-2027 are estimated at 678 million RMB, 621 million RMB, and 786 million RMB respectively, with net profits of 42 million RMB, 64 million RMB, and 80 million RMB [2][6]. - The company anticipates a peak sales potential of 1.5 billion USD for Pimiatinib targeting TGCT and 1 billion USD for cGVHD [6]. - The report highlights a significant increase in revenue growth rate from 2,544% in 2023 to 35% in 2024, followed by a slight decline of 8% in 2025, and a rebound of 27% in 2026 [9][10]. Product Pipeline and Market Potential - The company is advancing its pipeline with ABSK011, a potential first-in-class FGFR4 inhibitor, which has shown promising preclinical efficacy and is currently in registration clinical trials [5]. - ABSK043, an oral PD-L1 inhibitor, is also in development, showing a 19.6% objective response rate in early trials, with potential for significant market impact in the NSCLC segment [7]. - The company has a rich pipeline with various candidates, including KRAS inhibitors and ADCs, indicating a strong future growth trajectory [7].

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年8月31日 狀態: 新提交 致：香港交易及結算所有限公司 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02256 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 5,000,000,000 | USD | | 0.00001 | USD | | 50,000 | | 增加 / 減少 (-) | | | | | | | USD | | | | 本月底結存 | | | 5,000,000,000 | USD | | 0.00001 | USD | | 50,000 | 本月底法定/註冊股本總額： USD 50,000 FF301 第 1 頁 共 10 頁 v ...

Core Viewpoint - The company, He Yu-B (02256.HK), has entered into agreements with J.P. Morgan Securities plc to subscribe to redeemable zero-coupon notes issued by JPMorgan Chase Bank, N.A., with a subscription amount of 10 million USD [1] Group 1 - On July 9, 2025, the company agreed to subscribe to USD notes linked to the offshore RMB exchange rate issued by J.P. Morgan Structured Products B.V., with a subscription amount of 10 million USD [1] - The outstanding balance of the notes linked to the offshore RMB exchange rate prior to the subscription of the redeemable zero-coupon notes is approximately 10 million USD [1]

Core Viewpoint - The company has entered into agreements with J.P. Morgan Securities plc to subscribe to two different types of notes, indicating a strategic move to manage its financial instruments and exposure to currency fluctuations [1] Group 1: Financial Agreements - The company agreed to subscribe to redeemable zero-coupon notes issued by JPMorgan Chase Bank, N.A. for an amount of 10 million USD [1] - Prior to the subscription of the redeemable zero-coupon notes, the company entered into an agreement to subscribe to USD notes linked to the offshore RMB exchange rate, also for an amount of 10 million USD [1] - The outstanding balance of the notes linked to the offshore RMB exchange rate before the subscription of the redeemable zero-coupon notes is approximately 10 million USD [1]

格隆汇8月28日丨和誉-B(02256.HK)发布公告，2025年8月28日耗资159.37万港元回购10万股，回购价格 每股15.9-15.99港元。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容所產生或因依 賴該等內容而引致的任何損失承擔任何責任。 Abbisko Cayman Limited 和譽開曼有限責任公司 （於開曼群島註冊成立的有限公司）） （股份代號：2256） 須予披露交易 認購理財產品 認購理財產品 董事會宣佈，於2025年8月28日，本公司與J.P. Morgan Securities plc訂立協議， 據此，本公司同意認購JPMorgan Chase Bank, N.A.發行的美元可贖回零息票 據，認購金額為10.0百萬美元。 認購美元可贖回零息票據前，於2025年7月9日，本公司與J.P. Morgan Securities plc訂立協議，據此，本公司同意認購由J.P. Morgan Structured Products B.V.發 行的與美元兌離岸人民幣匯率掛鈎的美元票據，認購金額為10.0百萬美元。緊 接認購美元可贖回零息票據前，認購與美元兌離岸人民幣匯率掛鈎的美元票據 的尚未償還總結餘約為10.0百萬美元。 上市規則 ...

Group 1 - The company, He Yu-B (02256), announced a share buyback of 100,000 shares at a cost of approximately HKD 1.5937 million on August 28, 2025 [1]

Core Viewpoint - Company He Yu-B (02256) announced a share buyback plan, indicating a strategic move to enhance shareholder value through the repurchase of shares [1] Group 1 - The company plans to repurchase 100,000 shares [1] - The total expenditure for the buyback is approximately HKD 1.5937 million [1] - The buyback is scheduled to occur on August 28, 2025 [1]